一、 关于会议

临床上超过20%的不同类型的癌症是由病毒引起的。80%以上的肝癌是由乙肝病毒(HBV)和丙肝病毒(HCV)所致。人类乳头状瘤病毒(HPV)是宫颈癌和其他阴道肿瘤及头颈部肿瘤的罪魁祸首。人类多瘤病毒，如BK多瘤病毒，与肾癌和膀胱癌的发生相关。爱泼斯坦巴尔病毒(EBV)是鼻咽癌、何杰金氏淋巴瘤以及伯基特淋巴瘤发生的主要原因。人类疱疹病毒8(HHP8)在免疫功能低下患者体内引起卡波西肉瘤的生成。人类T细胞白血病毒1(HTLV-1)会导致成人T细胞淋巴瘤。一般来说，肿瘤病毒通过多种机制引起癌症，包括破坏宿主的遗传性和表观遗传性的完整和体内平衡，干扰细胞DNA修复机制导致基因组的不稳定和抑癌基因的突变,以及使正常的细胞信号通路失活等。然而，人类对特定细胞基因的重要性和潜在的分子机制和信号通路在病毒性肿瘤发生中的作用知之甚少。当前，治疗各种癌症的新药正在不断被研发。我们期待本届高峰论坛将不仅作为促进科学交流，促进中国和其他发达国家的科学家们之间的合作平台,更期待它能够促进抗癌新药的发现和开发。

由南京生物医药谷主办、南京高新生物医药公共服务平台承办的“2016年第二届国 际病毒性肿瘤暨新药研发高峰论坛”将于2016年9月16-18日在文化科教名城江苏省南京 市召开。此次学术盛会有幸邀请到中国工程院庄辉院士和王红阳院士、中国科学院高福院 士、美国科学院Patrick Moore院士、美国肝脏移植中心主任在内的多位享誉世界的专家学者作为演讲嘉宾。目标 参会者为病毒及肿瘤研究专家、新药研发专家、三甲医院科室主任，以及对肿瘤病毒的基 础和临床研究或治疗及新药研发有兴趣的科研人员、临床医生和研究生。本次高峰论坛将 为中美两国在病毒肿瘤的分子生物学和抗病毒抗肿瘤新药研发方面的科学家们，提供相互 交流最新研究成果并探讨合作机会的学术平台。同时，我们也为优秀论文摘要递交者预留 了充裕的发言时间，为他们提供展示最新研究成果的机会。会议还特别安排了讨论中美合 作机制的圆桌会议，为两国科学家们探讨如何根治乙肝并展开合作提供建言献策平台。会议期间，将会由PLoS Pathogens 杂志社主编讲授论文写作及投稿技巧。本次高峰论坛 大咖云集，内容丰富，精彩纷呈，我们诚挚邀请您前来参会！

会议期间美国国立卫生院驻中国办事处代表、国家科技部交流中心美大处处长、国家自然科学基金委员会医学科学处处长将悉数到会。本届会议旨在促进中美两国科学家交流合作、促进科技进步、建立两国间的合作机制。

二、会议组织

1、大会主席Co-Chairs: 

Guangxiang(George) Luo, Endowed Professor, University of Alabama at Birmingham School of Medicine and Peking University health Science Center, Section Editor of PLoS Pathogens and Associate-Editor of Journal of Medical Virology

罗光湘,美国伯明翰阿拉巴马大学医学院微生物学系终身教授及综合癌症中心和AIDS中心资深研究员，同时兼任北京大学医学部“千人计划”特聘教授。现主要从事肝炎病毒和肝癌的分子生物学研究及创新药物研发。目前为《PLoS Pathogens》 Section Editor和《Journal of Medical Virology》Associate Editor，及《Journal of Virology》，《Virology》，《中华医学杂志》和《中国病毒学杂志》等多种国际杂志的编委。

Professor Guangxiang (George) Luo graduated from Hunan Medical College in 1983 and completed his postdoctoral training with Prof. John M. Taylor at Fox Chase Cancer Center in Philadelphia (1988-1990) and Prof. Peter Palese at Mt. Sinai School of Medicine in New York City (1990-1992). He then worked at Bristol-Myers Squibb Pharmaceutical Research Institute as a senior investigator. In 2000, he joined the department of Microbiology, Immunology and Molecular Genetics at the University Of Kentucky College Of Medicine as an associate professor and was promoted to tenured full professor in 2006. In 2012, he moved to the University of Alabama at Birmingham (UAB)School of Medicine. Currently, he is an Endowed Professor in the Department of Microbiology, member of the UAB CFAR executive committee, and senior scientist at the UAB Comprehensive Cancer Center. In 2011, he became a joined faculty in the Department of Microbiology at Peking University Health Science Center. 

庄辉，中国工程院院士，现任北京大学医学部病原生物学系教授、世界卫生组织西太区消灭脊髓灰质炎证实委员会委员、世界卫生组织西太区免疫控制乙型肝炎专家组成员、亚太消灭病毒性肝炎联盟委员、国家药典委员会委员等职。发表论文650余篇，参编英文专著5册，中文专著30册。曾获美国专利1项、国家科技进步二等奖4项、国家新药证书3项、省部级奖多项。

Professor Hui Zhuang graduated from the First Moscow Medical Institute, Russia. He is currently a Professor at the Department of Microbiology, Peking University Health Science Center. Professor Zhuang is also a member of the Regional Commission for Certification of Poliomyelitis Eradication in Western Pacific, WHO; a member of the Western Pacific Region Expert Resource Panel on Hepatitis B Control Through Immunization (ERP HEPB), WHO; a member of the Council of the Coalition to Eradicate Viral Hepatitis in Asia Pacific; a member of the National Pharmacopoeia Commission, China. Professor Zhuang is also a member of Chinese Academy of Engineering, which is the highest academic title and a life-long honor. He has obtained one patent from the United States and one patent from the National Patent Office, China. The Ministry of Science and Technology has awarded Professor Zhuang four National Prizes of Science and Technology, several prizes of Science and Technology by the Ministry of Public Health, and by the Ministry of Education, as well as from the Beijing Municipal Government; and three Certificates of New Drugs from the State Food and Drug Administration, China. 

James Jing-Hsiung Ou, University of Southern California(USC), Editor of Journal of Virology

Dr. Ou received his B.S. degree from the National Taiwan University in 1976 and his Ph.D. from the California Institute of Technology in1982. He conducted his postdoctoral research at UC San Francisco and joined the Department of Molecular Microbiology and Immunology at the University of Southern California in 1986. He is currently a professor in the Department of Molecular Microbiology and Immunology and the Associate Director of the Institute of Emerging Pathogens and Immune Diseases at USC.

Presentation Title:

Mechanism of hepatitis B virus persistence in the offspring after vertical transmission

Abstract:

Patients who acquired hepatitis B virus (HBV) from their mother through vertical transmission frequently become chronic HBV carriers. In contrast, patients acquired the virus from other adults via horizontal transmission often develop self-limited acute infection. To understand the difference between these two types of transmission son HBV, we developed a mouse model to study the possible effect of maternal HBV on HBV persistence in the offspring. We found that HBV carried by the mother impaired CD8⁺ T cell responses to HBV in her offspring, resulting in HBV persistence. This impairment of CD8⁺ T cell responses required the expression of the HBV e antigen (HBeAg) in both the mother and the offspring and was associated with the increase of PD-1 expression in CD8⁺ T cells and the increase of PD-L1 expression in hepatic macrophages. Further analysis indicated that the maternal HBeAg could predisposehepatic macrophages of the off spring to undergo the M2 polarization to support HBV persistence when these cells were re-stimulated by HBeAg. Our studies thus delineated an important function of HBeAg in HBV persistence after vertical transmission. Moreover, as the disruption of the interaction between PD-1 andPD-L1 with theanti-PD-L1antibody or the depletion of hepatic macrophages led to the activation of CD8⁺T cells and HBV clearance, our results also raised the possibility of target ingmacrophages to treat chronic HBV patients. 

Dr. Jim Wu is CEO and chairman of board of Ark Biosciences, a biotech company that focuses on antiviral drug discovery and clinical development. 

Dr. Wu has 19year’s pharma experience in which he contributed to development of antiviral, oncology and CNS drugs, including three phase 3 drugs, three phase 2 drugs and Potiga/Trobalt™ that was approved by both FDA and EMEA in 2011. Dr. Wu was director of preclinical and translational research and scientific advisor to global marketing group at Valeant Pharmaceuticals, a founding scientist of Ribapharm that went IPO at NYSE in 2002 for USD 800 million, and a senior scientist at Schering-Plough Research Institute, now part of Merck. More recently, he was a member of China management team, senior director, head of biology/virology at Roche Pharm Research and Early Development (China), where he held responsibility for drug discovery, external collaboration, and management. 

Dr. Wu obtained his BSc from University of Science and Technology of China, his PhD from Brown University, and conducted postdoctoral research at Harvard Medical School. He is a coauthor of 60s scientific papers and serves in the editorial advisory board of “Antimicrobial Agent and Chemotherapy”. He is also an adjunct professor at Fudan University School of Pharmacy and Shanghai Medical College. In his pharma industrial career, he is a co-inventor of 12 patents and contributed to 4 INDs and 2 NDAs.

2、主办方

南京生物医药谷

3、承办方

南京高新生物医药公共服务平台有限公司

三、会议日程

四、网上投稿：

凡未公开发表并与本次会议议题相关的研究论文均可投稿。

截止日期：

所有投稿需在2016年7月31日前完成。

摘要格式：

摘要语言为英文，建议字数（包括内容及致谢）不超过500字。具体格式请前往会议官网下载‘摘要模板’。

壁报制作及展示要求

所有投稿的会议摘要经评选委员会初步审查接收后，均参加壁报展示交流。壁报语言为英文，展示安排在会议期间进行。会议现场提供壁报展板及大头针/双面胶，壁报规格为1.5 米高、0.9 米宽。

壁报张贴于9 月15 日下午2点后开始进行，请各位壁报展示者根据提供的壁报编号在指定展板位置进行张贴， 9月18日下午2点后除下壁报。

五、报名费用： 

（包含参会费、9.16-9.18的午餐、9.16-9.17的晚餐、茶歇数次、18日下午参观游玩活动）差旅交通、住宿、早餐需自理。

退费政策：须以书面形式提交取消参会申请，并于9月4日24:00前发送邮件至meeting@biopharmpt.com，可享受全额退费；9月5日-9月11日24:00前取消参会将收取20%手续费；9月11日24：00后取消参会将不退还任何费用，敬请谅解。

六、缴费方式：

A．电汇或网银

单位名称：南京高新生物医药公共服务平台有限公司

开户行：建设银行南京高新技术开发区支行

账　号：3200 1596 5360 5250 6630

B、支付宝转账

支付宝账号：13851495914@163.com

C、Bank Name: AGRICULTURAL BANK OF CHINA NANJING BRANCH

Bank Headquarters City: BEIJING

Bank Branch Address: NO.11 WENDE EAST STREET PUKOU DISTRICT NANJING CHINA

Account Holder and Address: NANJING BIOPHARMACEUTICAL INNOVATION PLATFORM CO., LTD

Add：3-1 Xin Jin Hu Road，Building B，Room 710，Pukou，Nanjing，Jiangsu，210061，China

Account Number/IBAN: 10122014040002655

Swift Code: ABOCCNBJ100

Currency: USD